10-Q: Nordicus Partners Corporation Reports Q3 Results, Completes Acquisitions of Orocidin and Bio-Convert

Nordicus Partners Corporation files its quarterly report, highlighting acquisitions and financial results for the period ending December 31, 2024.

Summary

• Nordicus Partners Corporation filed its Form 10-Q for the quarter ended December 31, 2024.
• The company completed the acquisitions of Orocidin A/S and Bio-Convert ApS during the quarter.
• The company reported revenue of $2,500 for the three and nine months ended December 31, 2024.
• Operating expenses increased significantly due to officer compensation, professional fees, consulting expenses, general and administrative expenses, and research and development costs.
• The net loss attributable to Nordicus Partners Corporation was $(1,535,963) for the three months ended December 31, 2024, and $(2,294,917) for the nine months ended December 31, 2024.
• The company had cash of $28,001 as of December 31, 2024, compared to $49,933 as of March 31, 2024.
• The company issued 12,000,000 restricted shares of common stock for the acquisition of Bio-Convert.
• The company issued 200,000 restricted shares of common stock to acquire the remaining equity of Orocidin.
• The company effectuated a 1-for-10 reverse stock split on November 8, 2024.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company has made strategic acquisitions, the increased losses and ineffective disclosure controls raise concerns.

Positives

• The acquisitions of Orocidin A/S and Bio-Convert ApS provide Nordicus Partners Corporation with a presence in the biopharmaceutical industry.
• The company acquired 100% of Orocidin A/S.

Negatives

• The company has nominal revenue and has incurred losses since inception resulting in an accumulated deficit of $46,178,444 as of December 31, 2024.
• The company's operating expenses have increased significantly.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Risks

• The company's ability to continue as a going concern is dependent on generating profitable operations and/or obtaining necessary financing.
• The company's operations are subject to factors that can affect its operating results and financial condition, including research and development results, regulatory approvals, competition, and the ability to raise capital.
• The company's disclosure controls and procedures were deemed not effective at the reasonable assurance level due to limited resources in the finance and accounting functions.

Future Outlook

The company's mission is to assist Nordic companies in realizing their growth strategy by improving systems and processes, sharpening commercial focus, and providing guidance for establishing themselves in the U.S. market.

Management Comments

• Our core competencies lie in assisting Danish as well as other Nordic and U.S. life science companies in different areas of corporate finance activities.
• Our mission going forward, is to assist the right Nordic companies realize their growth strategy, by fine tuning systems and processes, sharpening the commercial focus and providing companies with the best possible guidance and setup suited to successfully establish themselves on the U.S. market.

Industry Context

The company is operating in the financial consulting and biopharmaceutical industries, focusing on assisting Nordic companies in entering the U.S. market and developing treatments for periodontitis and oral leukoplakia.

Comparison to Industry Standards

• It is difficult to compare Nordicus Partners directly to industry standards due to its unique combination of financial consulting and biopharmaceutical activities.
• However, the company's financial performance can be compared to other small-cap companies in the consulting and biopharmaceutical sectors.
• For example, companies like Anavex Life Sciences Corp. and Cassava Sciences, Inc. are also clinical-stage biopharmaceutical companies, but they have different focuses and financial profiles.
• Consulting firms like McKinsey & Company and Boston Consulting Group are much larger and have different business models.

Management Changes

Related Party Transactions

• The company issued a warrant to GK Partners, a related party, to purchase up to 1,000,000 shares of common stock.
• Mr. Bennett Yankowitz, our chief financial officer and director, was affiliated with legal counsel who provided us with general legal services.

Stakeholder Impact

• Shareholders may be concerned about the increased losses and the need for additional financing.
• Employees of Orocidin and Bio-Convert may be affected by the integration of these companies into Nordicus Partners Corporation.

Next Steps

• The company intends to take appropriate and reasonable steps to make improvements to remediate the deficiencies in disclosure controls and procedures.
• The company will continue to develop and commercialize the products acquired through the Orocidin and Bio-Convert acquisitions.

Key Dates

Keywords

acquisitions, biopharmaceutical, Orocidin, Bio-Convert, financial results, Nordicus Partners, reverse stock split, operating expenses, net loss, stock issuance